司美格鲁肽注射液致急性便秘1例分析

doi:10.19803/j.1672-8629.20220584

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (7): 833-835.
DOI: 10.19803/j.1672-8629.20220584

司美格鲁肽注射液致急性便秘1例分析

秦桂兰, 周木子, 冀召帅, 毛乾泰, 艾超^*

清华大学附属北京清华长庚医院药学部,清华大学临床医学院,北京 102218

收稿日期:2022-09-30 出版日期:2023-07-15 发布日期:2023-07-14
通讯作者: ^*艾超,男,硕士,副主任药师,医院药事管理与精准化药学。E-mail：aichao@btch.edu.cn
作者简介:秦桂兰,女,本科,主管药师,医院药学。

One case of acute constipation induced by semaglutide injection

QIN Guilan, ZHOU Muzi, JI Zhaoshuai, MAO Qiantai, AI Chao^*

Department of Pharmacy, Beijing Tsinghua Changgung Hospital/School of Clinical Medicine, Tsinghua University, Beijing 102218, China

Received:2022-09-30 Online:2023-07-15 Published:2023-07-14

摘要/Abstract

摘要： 目的通过分析使用司美格鲁肽注射液致急性便秘病例,提出该药的用药警戒。方法对1例患者接受司美格鲁肽注射液治疗后发生急性便秘进行分析并提出用药建议。结果患者仅使用1次0.5 mg司美格鲁肽注射液,次日即出现急性便秘症状,经对症治疗后,便秘症状得到缓解。通过降低用量,未再发生便秘症状。根据患者的临床表现及用药时间的关联性,考虑是司美格鲁肽注射液导致了患者的急性便秘。结论司美格鲁肽注射液用于减重,在我国属于超说明书用药范畴,大剂量可能会导致急性便秘,建议按照说明书要求从小剂量开始治疗,并告知患者可能存在的不良反应,当出现不良反应时应及时就医。

关键词: 司美格鲁肽, 注射液, 急性便秘, 药品不良反应, 超说明书用药

Abstract: Objective To recommend measures of pharmacovigilance of semaglutide injection based on one case of acute constipation. Methods One case of acute constipation after semaglutide injection was analyzed, and a proper medication was recommended. Results The patient started with 0.5 mg semaglutide injection, but developed acute constipation symptoms the next day. After symptomatic treatment, the constipation symptoms were alleviated. After the dosage was reduced, constipation did not re-occur. Given the correlations between the patient’s clinical manifestations and the time of administration, the acute constipation was believed to have been caused by semaglutide injection. Conclusion Semaglutide injection is used for weight loss, which is off-label, so large doses may cause acute constipation. Clinicians are recommended to start with small doses according to the instructions, and inform the patients of possible adverse reactions. In case of adverse reactions, emergency medical treatment should be offered.

Key words: semaglutide, injection, acute constipation, adverse drug reaction, off-label use

中图分类号:

秦桂兰, 周木子, 冀召帅, 毛乾泰, 艾超. 司美格鲁肽注射液致急性便秘1例分析[J]. 中国药物警戒, 2023, 20(7): 833-835.

QIN Guilan, ZHOU Muzi, JI Zhaoshuai, MAO Qiantai, AI Chao. One case of acute constipation induced by semaglutide injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 833-835.

参考文献

[1] Chinese Diabetes Society.Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Diabetes(中华糖尿病杂志),2021,13(4):315-409.
[2] HAN MF,ZHAO B,CHEN W,et al.The mechanism and clinical application of semaglutide in obesity[J]. Chinese Journal of New Drugs(中国新药杂志),2022,31(9):859-862.
[3] JI LN,ZHOU DJ,HONG TP,et al.Expert guidance on clinical application of GLP-1 receptor agonist[J]. Chinese Journal of Diabetes(中国糖尿病杂志),2018,26(5):353-361.
[4] WADDEN TA,BAILEY TS,BILLINGS LK,et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial[J]. Journal of the American Medical Association,2021,325(14):1403-1413.
[5] WILDING JPH,BATTERHAM RL,CALANNA S,et al.Once-weekly semaglutide in adults with overweight or obesity[J]. The New England Journal of Medicine,2021,384(11):989-1002.
[6] RUBINO DM,GREENWAY FL,KHALID U,et al.Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial[J]. Journal of the American Medical Association,2022,327(2):138-150.
[7] LEEHEY DJ,RAHMAN MA,BOTYSE, et al. Acute kidney injuryassociated with semaglutide[J]. Kidney Medicine,2021,3(2):282-285.
[8] ENSLIN S, BARTELL N, KAUL V.The first reported case of drug-induced liver injury caused by semaglutide[J]. American Journal of Gastroenterology,2021,116:S1141.
[9] FARASAT S,MCCALLUM J.Semaglutide-induced leukocytoclastic vasculitis[J]. Endocrine Practice,2022,28(2):S21-S22.
[10] Drug Safety Supervision Department of State Food and Drug Administration, National Center for Adverse Drug Reaction. Manual for adverse drug reaction reporting and monitoring[S]. Being, 2012: 49.
[11] Gastrointestinal Dynamics Group,Society of Digestive Diseases,Chinese Medical Association.Colorectal and Anorectal Surgery Group,Surgical Society of Chinese Medical Association.Guidelines for the diagnosis and treatment of chronic constipation in China(Wuhan,2013)[J].Chinese Journal of Digestion(中华消化杂志),2013,33(5):291-297.
[12] YE GF.Diagnosis and treatment of drug-induced constipation[J]. Journal of North Pharmacy(北方药学),2013,10(10):21.
[13] FRIEDRICHSEN M,BREITSCHAFT A,TADAYON S,et al.The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating and gastric emptying in adults with obesity[J]. Diabetes,Obesity and Metabolism,2021,23(3):754-762.
[14] HALIM A,DEGERBLAD M,SUNDBOM M,et al.Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans[J]. The Journal of Clinical Endocrinology and Metabolism,2018,103(2):575-585.

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.

司美格鲁肽注射液致急性便秘1例分析

One case of acute constipation induced by semaglutide injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics